Compare Fortinet Inc (FTNT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs TG Therapeutics Inc — how do they compare? Fortinet Inc trades at $160.88 (market cap $118.78B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Fortinet Inc is far larger — about 15.5× TG Therapeutics Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FTNT | TGTX | |
|---|---|---|
Market Cap | $118.78B | $7.64B |
Sector | Technology | Health |
52-Week High | $168.29 | $59.06 |
52-Week Low | $75.23 | $26.94 |
Enterprise Value | $115.21B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $161.21, down 1.83% over 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $0.90 versus $0.746 expected, driven by robust demand for cybersecurity solutions amid AI-driven security needs. Revenue growth has accelerated from $4.4B in 2022 to $6.8B in 2025, with net income margins above 28%, though valuation ratios like P/E of 57.2 indicate premium pricing.
The outlook remains positive given consistent earnings beats and analyst consensus price target of $174.50, offering ~8% upside. Key risks include high valuation multiples, competitive pressures in cybersecurity, and negative net cash flow trends. Institutional sentiment is mixed with 42.65% buy ratings, but growth in AI security and SASE firewall adoption supports long-term potential.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
